RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07152782, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Histologically confirmed invasive HER2 positive breast cancer (HER2 IHC+++or FISH/CISH positive, all samples need to be verified by the pathology department of the research center).

    Inclusion criterion 4

  3. Due to ongoing grade ≥ 2 adverse reactions caused by previous treatments (excluding hair loss).

    Exclusion criterion 5

    Participated in clinical trials of other anti-tumor drugs within 4 weeks prior to the first use of the investigational drug.

    Exclusion criterion 10

  4. ECOG score ranges from 0 to 1.

    Inclusion criterion 2

  5. The standard for blood routine examination should meet: HB ≥ 90g/L (no blood transfusion within 14 days); ANC≥1.5×109/L;PLT≥75×109/L;

    Inclusion criterion 12

    Biochemical tests must meet the following standards: TBIL ≤ 1.5 × ULN (upper limit of normal value); ALT and AST ≤ 3 × ULN; If there is liver metastasis, ALT and AST should be ≤ 5 × ULN; Serum Cr ≤ 1.5 × ULN, endogenous creatinine clearance rate ≥ 30mL/min (Cockcroft Gault formula).

    Inclusion criterion 13

  6. Other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.

    Exclusion criterion 7

    Known subjects with active HBV or HCV infection.

    Exclusion criterion 12

    Active primary immunodeficiency, known to be HIV positive.

    Exclusion criterion 13

  7. Female participants with fertility agreed to take effective contraceptive measures until 3 months after the last use of medication.

    Inclusion criterion 15

    Pregnancy period.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07152782, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

-

Participants must meet all of the following inclusion criteria in order to be enrolled in this study:

  • Female, aged 18-70 years old.
  • ECOG score ranges from 0 to 1.
  • Expected survival period is greater than 12 weeks.
  • Histologically confirmed invasive HER2 positive breast cancer (HER2 IHC+++or FISH/CISH positive, all samples need to be verified by the pathology department of the research center).
  • Tumor staging: recurrent or metastatic breast cancer; Patients with local recurrence need to be confirmed by the researcher that radical surgical resection cannot be performed.
  • The subject has at least one lesion (measurable and/or unmeasurable) that has not received radiation therapy in the past.
  • MRI or CT shows brain metastasis and meets one of the following conditions:

i) Untreated brain parenchymal metastases detected through imaging screening;

Ii) Stable or progressive brain parenchymal metastases that have undergone previous local treatment and meet one of the following conditions:

  • Stable imaging for ≥ 4 weeks;
  • New brain parenchymal metastases detected by MR or CT.
  • Transfer treatment ≤ 2 lines, and did not receive T-DXd or nalatinib.
  • The main organ functions are basically normal, meeting the following conditions:
  • The standard for blood routine examination should meet: HB ≥ 90g/L (no blood transfusion within 14 days); ANC≥1.5×109/L;PLT≥75×109/L;
  • Biochemical tests must meet the following standards: TBIL ≤ 1.5 × ULN (upper limit of normal value); ALT and AST ≤ 3 × ULN; If there is liver metastasis, ALT and AST should be ≤ 5 × ULN; Serum Cr ≤ 1.5 × ULN, endogenous creatinine clearance rate ≥ 30mL/min (Cockcroft Gault formula).
  • Prior to enrollment, the use of mannitol and hormone therapy is allowed, but the medication dosage should be stable for at least one week without the need for an increase.
  • Female participants with fertility agreed to take effective contraceptive measures until 3 months after the last use of medication.
  • The subjects voluntarily joined this study, signed informed consent forms, had good compliance, and cooperated with follow-up.

Exclusion Criteria:

-

Subjects with any of the following conditions are not eligible for inclusion in this study:

  • Transfer treatment exceeding 2 lines, or previous use of T-DXd or nalatinib.
  • Meningeal metastasis.
  • Brain metastases that require emergency intervention treatment, or brain metastases that require treatment with more than 3mg/d dexamethasone or equivalent drugs.
  • A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina, myocardial infarction within the past 6 months, or ventricular arrhythmia.
  • Due to ongoing grade ≥ 2 adverse reactions caused by previous treatments (excluding hair loss).
  • Pregnancy period.
  • Other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.
  • Unable to swallow, chronic diarrhea, and intestinal obstruction, there are multiple factors that affect medication intake and absorption.
  • There is a third interstitial fluid accumulation that cannot be controlled by drainage or other methods (such as a large amount of pleural fluid and ascites).
  • Participated in clinical trials of other anti-tumor drugs within 4 weeks prior to the first use of the investigational drug.
  • Long term unhealed wounds or fractures with incomplete healing.
  • Known subjects with active HBV or HCV infection.
  • Active primary immunodeficiency, known to be HIV positive.
  • Uncontrolled infections requiring intravenous injection of antibiotics, antiviral drugs, or antifungal drugs.
  • A history of non communicable ILD/pneumonia requiring steroids, currently suffering from ILD/pneumonia, or unable to rule out suspected ILD/pneumonia through imaging during screening.
  • Lung standard:
  • Pulmonary specific comorbidities with clinically significant diseases, including but not limited to any potential pulmonary diseases (such as pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive pulmonary disease, pleural effusion, etc. within 3 months of recruitment).
  • Any autoimmune disease, connective tissue disease, or inflammatory disease (such as rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.). There are records or suspicions of lung involvement during screening. For participants participating in the study, all detailed information about the disease should be recorded in the CRF.
  • Previous complete lung resection surgery.
  • Individuals with allergies, or those with a known history of allergies to the components of this medication regimen, or subjects who are allergic to other monoclonal antibodies.

Researchers believe that substance abuse or medical conditions may interfere with participants' participation in clinical studies or the evaluation of clinical study results.

Quoted from ClinicalTrials.gov, NCT07152782, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07152782, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07152782